Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro
Mem. Inst. Oswaldo Cruz
;
104(3): 462-467, May 2009. tab
Article
in English
| LILACS
| ID: lil-517011
ABSTRACT
The clinical and epidemiological characteristics, adverse events, treatment adherence and effectiveness of isoniazid chemoprophylaxis were analyzed in a cohort of 138 tuberculosis/HIV-coinfected patients. An open, non-randomized, pragmatic prophylactic trial was conducted on adult patients with a normal chest X-ray and positive tuberculin skin test (> 5 mm) who received isoniazid chemoprophylaxis (300 mg/day) for six months. The mean of follow up was 2.8 years (SD 1.3). Adherence to chemoprophylaxis was 87.7 percent (121/138). Only one patient presented tuberculosis after the end of chemoprophylaxis, corresponding to 0.3 cases per 100 persons per year. The relative risk of some adverse effects was 4.6 times higher (95 percent CI 1.9-11.5) in patients with positive anti-HCV serology (4/9, 44.4 percent) compared to those with negative serology (12/129, 9.6 percent) (p = 0.002). This study provides evidence regarding the effectiveness and safety of a short and self-administered isoniazid regimen. We recommend the implementation of this routine by health service practitioners.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Tuberculosis
/
AIDS-Related Opportunistic Infections
/
Isoniazid
/
Antitubercular Agents
Type of study:
Controlled clinical trial
/
Etiology study
/
Incidence study
/
Observational study
/
Risk factors
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Mem. Inst. Oswaldo Cruz
Journal subject:
Tropical Medicine
/
Parasitology
Year:
2009
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Fundação Oswaldo Cruz/BR
Similar
MEDLINE
...
LILACS
LIS